OPEN ACCESS
International Medical Science Research Journal
P-ISSN: 2707-3394, E-ISSN: 2707-3408
Volume 4, Issue 7, P.No.771-787, July 2024
DOI: 10.51594/imsrj.v4i7.1356
Fair East Publishers
Journal Homepage: www.fepbl.com/index.php/imsrj

Harnessing the human microbiome: Probiotic and prebiotic interventions to reduce hospital-acquired infections and enhance immunity

Aliu Olalekan Olatunji[1], Janet Aderonke Olaboye[2], Chukwudi Cosmos Maha[3], Tolulope Olagoke Kolawole[4], & Samira Abdul[5]

[1]Independent Researcher, Ohio, USA
[2]Mediclinic Hospital Pietermaritzburg, South Africa
[3]Public Health Specialist, Albada General Hospital, Tabuk, Saudi Arabia
[4]Independent Researcher, Richmond, Virginia, USA
[5]University of North Florida, USA

Corresponding Author: Aliu Olalekan Olatunji
Corresponding Author Email: aliu_my2004@yahoo.com

Article Received: 28-02-24 **Accepted**: 02-06-24 **Published:** 26-07-24

ABSTRACT

Hospital-acquired infections (HAIs) represent a significant burden on healthcare systems, leading to increased morbidity, mortality, and healthcare costs. Recent advancements in microbiome research have highlighted the potential of probiotic and prebiotic interventions to mitigate HAIs and bolster immunity. This review explores the role of the human microbiome in health and disease, focusing on the promising strategies of utilizing probiotics and prebiotics to reduce HAIs. Probiotics, comprising live beneficial bacteria, can restore and maintain a balanced gut microbiota, potentially outcompeting pathogenic organisms and enhancing host immune responses. Prebiotics, however, are non-digestible food ingredients that selectively stimulate the growth and activity of beneficial bacteria in the gut. The synergistic effects of probiotics and prebiotics, known as symbiotic, offer an even greater potential for clinical application. Numerous studies have demonstrated the efficacy of specific probiotic strains, such as Lactobacillus and Bifidobacterium, in preventing infections and modulating immune functions. Furthermore, prebiotics like fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS) have shown to enhance the growth of probiotic bacteria, thus providing a twofold protective mechanism. The integration of these interventions into clinical practice could revolutionize the prevention and management of HAIs, reducing the reliance on antibiotics and mitigating the risk of antimicrobial resistance. However, challenges such as strain-specific effects, dosage optimization, and individual variability need to be addressed through rigorous clinical trials. This review underscores the need for further research and clinical validation to harness the full potential of the human microbiome in combating HAIs and enhancing patient outcomes through probiotic and prebiotic interventions.

Keywords: Human Microbiome, HAIs, Immunity.

INTRODUCTION

The human microbiome is the collection of all microorganisms, including bacteria, viruses, fungi, and their genes, that inhabit various parts of the human body, such as the skin, mouth, gut, and other mucosal surfaces (Dekaboruah *et al*., 2020; Abdul *et al*., 2024). It is estimated that the human body harbors trillions of these microorganisms, which outnumber human cells by approximately 10 to 1. The majority of these microbes are located in the gastrointestinal tract, particularly in the colon. This complex ecosystem plays a crucial role in various physiological processes, including digestion, synthesis of essential vitamins, and modulation of the immune system (García-Montero *et al*., 2021). The human microbiome is integral to maintaining health and preventing disease. A balanced microbiome contributes to the efficient functioning of metabolic processes, protects against pathogenic microbes, and supports the development and function of the immune system (Yoo *et al*., 2020; Olaboye *et al*., 2024). Dysbiosis, or an imbalance in the microbial community, has been linked to a range of health issues, including inflammatory bowel disease, obesity, diabetes, and even mental health disorders such as depression and anxiety (Mitrea *et al*., 2022; Oladimeji and Owoade, 2024). The microbiome's role in regulating immune responses is particularly significant, as it helps to protect the body from infections and maintain immune homeostasis (Wiertsema *et al*., 2021).

Hospital-acquired infections (HAIs), also known as nosocomial infections, are infections that patients acquire while receiving treatment for other conditions within a healthcare setting (Friedrich, 2019; Simpa *et al*., 2024). These infections typically occur 48 hours or more after hospital admission and can involve various pathogens, including bacteria, viruses, and fungi. Common types of HAIs include urinary tract infections, surgical site infections, bloodstream infections, and pneumonia (Voidazan *et al*., 2020). The prevalence of HAIs is a significant concern worldwide, with millions of cases reported annually, leading to substantial morbidity and mortality (Saleem *et al*., 2019). HAIs have a profound impact on patient outcomes and healthcare systems. They are associated with prolonged hospital stays, increased patient suffering, and a higher risk of complications and mortality. Moreover, HAIs contribute significantly to healthcare costs due to extended hospitalizations, additional diagnostic tests, and the need for more intensive treatments (Ogunbiyi *et al*., 2024). The financial burden is exacerbated by the growing problem of antimicrobial resistance, which makes infections harder to treat and leads to the use of more expensive and potentially toxic medications (Roope *et al*., 2019; Obiuto *et al*., 2024).

The purpose of this review is to explore the potential of probiotic and prebiotic interventions in reducing hospital-acquired infections and enhancing immunity. Probiotics are live microorganisms that confer health benefits to the host when administered in adequate amounts, primarily by restoring and maintaining a healthy microbiome (Zommiti *et al*., 2020; Abdul *et al*., 2024). Prebiotics, on the other hand, are non-digestible food components that selectively stimulate the growth and activity of beneficial gut bacteria. Together, these interventions can help to restore microbial balance, outcompete pathogenic organisms, and enhance the immune response (Okpokoro *et al*., 2023; Olaboye *et al*., 2024). This review aims to evaluate the efficacy of probiotic and prebiotic interventions in the context of HAIs. By reviewing current research and clinical trials, the review will assess how these interventions can be integrated into healthcare practices to prevent infections, reduce the use of antibiotics, and mitigate the risk of antimicrobial resistance. The ultimate goal is to provide a comprehensive overview of how harnessing the human microbiome through targeted probiotic and prebiotic strategies can improve patient outcomes and reduce the incidence of HAIs in healthcare settings.

The Human Microbiome and Immunity

The human microbiome consists of diverse microbial communities that inhabit various body sites, each with its unique composition and function (Ahrodia *et al*., 2022). The most densely populated microbial community is found in the gut, particularly in the colon, where trillions of bacteria reside. Dominant bacterial phyla in the gut include Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria (Alam *et al*., 2020). The skin microbiome, though less dense than the gut, is highly diverse and varies significantly between different body sites, influenced by factors such as moisture and sebaceous gland activity. Common skin bacteria include Staphylococcus, Corynebacterium, and Propionibacterium species. The respiratory tract also harbors distinct microbial communities, with the nasal passages and lungs populated by bacteria such as Streptococcus, Haemophilus, and Neisseria (Dimitri-Pinheiro *et al*., 2020; Simpa *et al*., 2024). Other significant microbial habitats include the oral cavity, with its own unique microbiota, and the urogenital tract, where Lactobacillus species predominate, particularly in females. The composition of the human microbiome is influenced by a myriad of factors, both intrinsic and extrinsic. Genetics play a role in determining baseline microbiome composition, influencing how individuals respond to different microbial exposures. Diet is a major external factor, with high-fiber, plant-based diets promoting a diverse and beneficial gut microbiome, while diets high in fat and sugar can lead to dysbiosis (Adanma and Ogunbiyi, 2024). Antibiotic use can profoundly disrupt microbiome composition, reducing microbial diversity and allowing opportunistic pathogens to thrive. Environmental factors, such as geography, hygiene practices, and exposure to different microbial communities, also shape the microbiome. Age and hormonal changes influence microbial populations as well, with significant shifts occurring from infancy to old age, and during events such as puberty and pregnancy (Bashir *et al*., 2022).

The human microbiome plays a crucial role in the development and function of the immune system. From birth, exposure to maternal and environmental microbes helps to shape the neonatal immune system. The gut microbiome, in particular, is integral to the maturation of the immune system, as it interacts with gut-associated lymphoid tissue (GALT), stimulating the production of immune cells and molecules (Roselli *et al*., 2022; Obiuto *et al*., 2024).

These interactions help to educate the immune system, promoting tolerance to benign antigens while enabling effective responses to pathogens. The skin and respiratory microbiomes also engage in constant dialogue with local immune cells, contributing to barrier immunity and systemic immune regulation. The microbiome modulates the immune system through several mechanisms. One key mechanism is the production of microbial metabolites, such as short-chain fatty acids (SCFAs) from dietary fiber fermentation in the gut. SCFAs, including acetate, propionate, and butyrate, have anti-inflammatory properties and can influence the function of regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance (Okpokoro *et al*., 2022; Abdul *et al*., 2024). The microbiome also influences the production of antimicrobial peptides and the integrity of the epithelial barrier, enhancing defense against pathogens. Additionally, certain gut bacteria can produce molecules that mimic host immune signals, directly modulating immune cell activity. For example, Bacteroides fragilis produces polysaccharide A, which has been shown to promote the development of Tregs and suppress inflammatory responses. Overall, the human microbiome is a key regulator of immune function, maintaining a delicate balance between immune activation and tolerance. Understanding the intricate relationship between the microbiome and the immune system offers potential therapeutic avenues for enhancing immunity and preventing diseases associated with immune dysregulation (Zheng *et al*., 2020; Olaboye, 2024).

Hospital-Acquired Infections (HAIs)

Surgical site infections (SSIs) occur at the site of a surgical incision and are among the most common HAIs (Seidelman and Anderson, 2021). They can be superficial, involving only the skin, or deeper, affecting tissues under the skin, organs, or implanted material. SSIs often arise from bacteria such as Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA), and can lead to complications such as delayed wound healing, extended hospital stays, and increased mortality. Preventing SSIs involves strict adherence to aseptic techniques, proper skin antisepsis, and appropriate use of prophylactic antibiotics. Urinary tract infections (UTIs) are another prevalent type of HAI, particularly among patients with indwelling urinary catheters (Krocová and Prokešová, 2022). Catheter-associated urinary tract infections (CAUTIs) are primarily caused by bacteria such as Escherichia coli, Klebsiella, and Enterococcus species. These infections can lead to serious complications, including pyelonephritis and bacteremia. Prevention strategies for CAUTIs focus on minimizing catheter use, ensuring proper catheter insertion and maintenance, and timely removal of catheters. Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are significant causes of morbidity and mortality in hospitalized patients. These infections are typically caused by bacteria such as Pseudomonas aeruginosa, Staphylococcus aureus, and Enterobacter species. Risk factors for HAP and VAP include mechanical ventilation, prolonged hospitalization, and underlying lung disease. Prevention measures include elevating the head of the bed, daily assessment of readiness to wean off ventilation, and implementing strict hand hygiene and infection control protocols. Bloodstream infections (BSIs), including central line-associated bloodstream infections (CLABSIs), occur when bacteria or fungi enter the bloodstream, often through vascular catheters (Selby *et al*., 2024; Simpa *et al*., 2024). Common pathogens include coagulase-negative staphylococci, Staphylococcus aureus, and Candida species. BSIs can lead to severe sepsis and septic shock, significantly increasing the risk of death. Preventing CLABSIs involves using aseptic techniques during catheter insertion, proper catheter site care, and removing unnecessary catheters as soon as possible.

Several patient-related factors increase the risk of HAIs. Immunocompromised individuals, such as those undergoing chemotherapy or organ transplantation, are particularly susceptible (Roberts and Fishman, 2021; Gannon *et al*., 2023). Other risk factors include advanced age, chronic diseases (e.g., diabetes, chronic obstructive pulmonary disease), malnutrition, and prolonged hospital stays. Surgical patients, especially those undergoing lengthy or complex procedures, are also at higher risk. These factors contribute to a weakened immune system or provide opportunities for pathogens to enter the body. Hospital-related factors play a significant role in the incidence of HAIs. High patient-to-staff ratios can lead to lapses in infection control practices. The presence of invasive devices, such as catheters and ventilators, increases the risk of infection. Contaminated hospital environments, including surfaces, medical equipment, and water systems, can harbor pathogens (Yiek *et al*., 2021). Inadequate cleaning, disinfection, and sterilization practices further exacerbate the risk. Additionally, the misuse or overuse of antibiotics contributes to the development of antimicrobial-resistant organisms, complicating the treatment of HAIs.

Standard infection control measures are crucial in preventing HAIs. These include strict hand hygiene practices using alcohol-based hand rubs or soap and water, using personal protective equipment (PPE) such as gloves and gowns, and following aseptic techniques during invasive procedures (Wyeth, 2022; Adanma and Ogunbiyi, 2024). Environmental cleaning and disinfection, proper sterilization of medical equipment, and isolation of infected patients are also essential components. The implementation of antimicrobial stewardship programs helps optimize the use of antibiotics, reducing the risk of resistance. Despite comprehensive infection control measures, several limitations and challenges persist. Adherence to protocols can be inconsistent, and lapses in hand hygiene and aseptic techniques still occur. The emergence of multidrug-resistant organisms poses a significant challenge, as they limit the effectiveness of available treatments. Additionally, the constant influx of new patients and the presence of asymptomatic carriers complicate infection control efforts. Ensuring continuous education and training of healthcare workers, alongside the development of new antimicrobial agents and alternative therapies, is critical to overcoming these challenges (Dhingra *et al*., 2020; Obiuto *et al*., 2024). HAIs remain a significant threat to patient safety and healthcare systems. Understanding the common types of HAIs, identifying risk factors, and implementing effective prevention and treatment strategies are essential to reducing their incidence and improving patient outcomes (Abdul *et al*., 2024). However, addressing the limitations and challenges requires ongoing efforts and innovations in infection control practices and antimicrobial therapy.

Probiotic Interventions

Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host (Melara *et al*., 2022). They are commonly found in fermented foods, dietary supplements, and are increasingly recognized for their potential therapeutic applications. The concept of probiotics stems from the understanding that a balanced microbiome plays a crucial role in maintaining health and preventing disease. By introducing beneficial bacteria into the body, probiotics aim to restore and maintain this balance, particularly in environments where the natural microbiota has been disrupted. Several bacterial strains are commonly used as probiotics in healthcare settings. These include species from the genera Lactobacillus and Bifidobacterium, which are prevalent in the gut microbiota and known for their health-promoting properties (Averina *et al*., 2021). Lactobacillus species, such as *Lactobacillus rhamnosus* and *Lactobacillus acidophilus*, are widely studied for their ability to inhibit pathogen growth and modulate the immune system. Bifidobacterium species, like *Bifidobacterium longum* and *Bifidobacterium breve*, are also popular due to their role in enhancing gut health and protecting against infections. Additionally, *Saccharomyces boulardii*, a beneficial yeast, is used for its probiotic effects, particularly in preventing and treating gastrointestinal disorders.

One primary mechanism through which probiotics exert their beneficial effects is by competing with pathogenic microorganisms for nutrients and adhesion sites on mucosal surfaces. By colonizing these niches, probiotics prevent harmful pathogens from establishing themselves and causing infections (Krawczyk *et al*., 2021; Olaboye, 2024). This competitive exclusion reduces the risk of infections, particularly in the gastrointestinal and urogenital tracts, where pathogen overgrowth can lead to severe health issues. Probiotics play a significant role in modulating the immune system. They can enhance both innate and adaptive immune responses, leading to improved pathogen clearance and reduced inflammation. Probiotics stimulate the production of antimicrobial peptides and promote the activity of immune cells, such as macrophages, dendritic cells, and T-lymphocytes. For instance, certain Lactobacillus strains have been shown to increase the production of cytokines, which are crucial for coordinating immune responses. This modulation helps in maintaining immune homeostasis and prevents overactive inflammatory responses that can lead to tissue damage. Probiotics contribute to the enhancement of mucosal barrier function, which is vital for protecting against pathogens and toxins (Gou *et al*., 2022). They strengthen the epithelial barrier by promoting the production of tight junction proteins that seal the gaps between epithelial cells (Okpokoro *et al*., 2022). This barrier function is crucial in preventing the translocation of pathogens and harmful substances from the gut lumen into the bloodstream. Additionally, probiotics stimulate the production of mucus, which traps pathogens and facilitates their removal from the body.

Numerous studies have investigated the efficacy of probiotics in preventing hospital-acquired infections (HAIs) (Kleintjes *et al*., 2020; Blot *et al*., 2022; Adanma and Ogunbiyi, 2024). Research has shown that probiotics can reduce the incidence of ventilator-associated pneumonia (VAP) and Clostridium difficile infections (CDIs). For example, a meta-analysis of clinical trials found that probiotics significantly lowered the risk of VAP in critically ill patients. Another study demonstrated that the administration of Lactobacillus and Bifidobacterium strains reduced the recurrence of CDIs, highlighting the potential of probiotics in managing antibiotic-resistant infections. Probiotics have been shown to enhance immune responses, thereby reducing susceptibility to infections. Clinical trials have demonstrated that probiotics can reduce the duration and severity of respiratory infections, such as the common cold and influenza (Obiuto *et al*., 2022; Dahiya and Nigam, 2023). For instance, a randomized controlled trial found that children who consumed probiotic-enriched milk had fewer and less severe respiratory infections compared to those who did not. These findings suggest that probiotics can strengthen the immune system, providing an additional layer of protection against infections. Several case studies and clinical trials provide evidence supporting the use of probiotics in healthcare. In one notable case study, a patient with recurrent urinary tract infections (UTIs) experienced significant improvement after receiving a probiotic supplement containing Lactobacillus rhamnosus. Additionally, clinical trials have shown that probiotics can prevent and treat gastrointestinal disorders, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) (Abdul *et al*., 2024). These trials underscore the therapeutic potential of probiotics in various health conditions, reinforcing their role in modern medicine.

Probiotics offer a promising intervention for preventing HAIs and enhancing immunity. Through mechanisms such as pathogen competition, immune modulation, and enhancement of mucosal barrier function, probiotics can significantly improve health outcomes. Clinical evidence supports their efficacy in reducing infection rates and strengthening immune responses, making them valuable tools in healthcare settings (Olaboye, 2024). Ongoing research and clinical trials continue to expand our understanding of probiotics, paving the way for their broader application in disease prevention and treatment.

Combined Probiotic and Prebiotic (Synbiotic) Approaches

Synbiotics are a combination of probiotics and prebiotics designed to synergistically enhance the growth and activity of beneficial microorganisms in the gut (Adanma and Ogunbiyi, 2024). Probiotics are live beneficial bacteria that, when ingested in adequate amounts, confer health benefits. Prebiotics are non-digestible food components that selectively stimulate the growth and activity of these beneficial bacteria. The rationale behind synbiotics is to combine these two interventions to maximize their positive effects on the host’s health. By providing both the beneficial bacteria (probiotics) and the substrates they need to thrive (prebiotics), synbiotics aim to improve gut health more effectively than either component alone. The combination of probiotics and prebiotics in synbiotics can produce synergistic effects that enhance their individual benefits. Probiotics help to restore and maintain a healthy microbial balance in the gut, while prebiotics provide the necessary nutrients for these beneficial bacteria to grow and function optimally. This synergistic relationship can lead to improved colonization and persistence of probiotics in the gut, enhanced production of beneficial metabolites like short-chain fatty acids (SCFAs), and a more robust immune response (Amabebe and Anumba, 2020; Obiuto *et al*., 2024). Additionally, synbiotics can help to outcompete pathogenic bacteria more effectively, reducing the risk of infections and promoting overall gut health.

Several studies have demonstrated the potential of synbiotics in preventing hospital-acquired infections (HAIs). Research has shown that synbiotics can reduce the incidence of infections such as ventilator-associated pneumonia (VAP) and Clostridium difficile infections (CDIs) (Sharif *et al*., 2022). For example, a clinical trial involving critically ill patients found that those who received a synbiotic supplement had a significantly lower incidence of VAP compared to those who received a placebo. Another study showed that synbiotics could reduce the recurrence of CDIs by restoring a healthy gut microbiota and inhibiting the growth of pathogenic bacteria. Synbiotics have also been shown to enhance immune responses, making them effective in reducing susceptibility to infections. Clinical trials have demonstrated that synbiotics can improve various aspects of the immune system, including the production of antimicrobial peptides, modulation of cytokine levels, and enhancement of

the gut barrier function (Abdul *et al*., 2024). For instance, a study involving elderly individuals found that those who consumed a synbiotic supplement had improved immune parameters and a reduced incidence of respiratory infections. This suggests that synbiotics can strengthen the immune system, providing an additional layer of protection against infections.
Several case studies and clinical trials provide evidence supporting the use of synbiotics in healthcare (Newman and Arshad, 2020; Olaboye *et al*., 2024). In one notable case study, patients with irritable bowel syndrome (IBS) experienced significant improvement in symptoms after receiving a synbiotic supplement containing Bifidobacterium and fructo-oligosaccharides (FOS). Additionally, a clinical trial involving patients undergoing colorectal surgery found that those who received a synbiotic supplement had a lower incidence of postoperative infections and a shorter hospital stay compared to those who did not receive the supplement. These findings underscore the therapeutic potential of synbiotics in various health conditions and highlight their role in enhancing patient outcomes.
Synbiotics offer a promising intervention for preventing HAIs and enhancing immunity. By combining probiotics and prebiotics, synbiotics can produce synergistic effects that improve gut health, boost the immune system, and reduce the risk of infections (Li *et al*., 2021; Cattaruzza *et al*., 2023). Clinical evidence supports their efficacy in various settings, making them valuable tools in modern healthcare. Ongoing research and clinical trials continue to expand our understanding of synbiotics, paving the way for their broader application in disease prevention and treatment.

Implementation in Clinical Practice

The integration of probiotics and prebiotics into hospital protocols requires the development of comprehensive guidelines to ensure their safe and effective use. These guidelines should be based on the latest scientific evidence and tailored to the specific needs of different patient populations. Key components should include. Recommendations on the specific strains and formulations that have been clinically validated for their efficacy and safety in preventing and managing hospital-acquired infections (HAIs) and enhancing immune function. Detailed instructions on the appropriate dosages, timing, and methods of administration for different patient groups, including critically ill patients, surgical patients, and those with compromised immune systems (Timsit *et al*., 2020; Adanma and Ogunbiyi, 2024). Protocols for monitoring patient outcomes, adverse effects, and overall effectiveness of the probiotic and prebiotic interventions. This should include regular microbiological assessments and clinical evaluations. Clear guidance on identifying patients who may be at risk of adverse reactions or for whom probiotic and prebiotic use may be contraindicated, such as those with severe immunosuppression or certain gastrointestinal conditions.
Successful implementation of probiotic and prebiotic interventions in clinical practice necessitates thorough training and education for healthcare professionals. This includes. Educating healthcare providers about the science behind probiotics and prebiotics, their mechanisms of action, and the clinical evidence supporting their use (Obiuto *et al*., 2024). This can be achieved through workshops, seminars, and continuing medical education (CME) programs. Training on how to integrate these interventions into daily clinical practice, including patient selection, administration protocols, and monitoring for efficacy and safety. Promoting collaboration among different healthcare professionals, such as doctors, nurses, dietitians, and pharmacists, to ensure a coordinated and holistic approach to patient care.

Safety and quality control are paramount when implementing probiotic and prebiotic interventions (Olaboye *et al*., 2024). Key considerations include. Ensuring that probiotic and prebiotic products meet stringent quality standards for purity, potency, and consistency. This requires adherence to regulatory guidelines and certification by recognized bodies. Although rare, there is a risk of infections caused by probiotic strains, particularly in immunocompromised patients. Rigorous screening and selection of strains with a proven safety profile are essential. Monitoring for potential adverse reactions, such as gastrointestinal discomfort or allergic responses, and establishing protocols for managing these effectively. Patient compliance and acceptance are critical factors in the success of probiotic and prebiotic interventions (Nwankwo and Ihueze, 2018). Strategies to enhance compliance include. Providing clear and comprehensive information to patients and their families about the benefits and potential risks of probiotic and prebiotic use. This can help in building trust and encouraging adherence to prescribed regimens. Developing formulations that are palatable and easy to consume, such as flavored supplements, capsules, or integrated into familiar foods and beverages. Actively addressing any concerns or misconceptions patients may have about probiotic and prebiotic products, such as fears of side effects or skepticism about their efficacy (Olaboye *et al*., 2024). The cost-effectiveness and accessibility of probiotic and prebiotic interventions are important considerations for widespread implementation. Key points include. Conducting comprehensive cost-benefit analyses to demonstrate the economic advantages of probiotic and prebiotic use, such as reduced incidence of HAIs, shorter hospital stays, and decreased reliance on antibiotics. Advocating for insurance coverage and reimbursement for probiotic and prebiotic products, highlighting their potential to reduce overall healthcare costs by preventing infections and improving patient outcomes. Ensuring that high-quality probiotic and prebiotic products are readily available and accessible to all patient populations, including those in resource-limited settings (Obiuto *et al*., 2024). This may involve partnerships with manufacturers and suppliers to reduce costs and improve distribution.

The implementation of probiotic and prebiotic interventions in clinical practice holds significant promise for enhancing patient outcomes and preventing hospital-acquired infections. However, this requires careful planning, education, and adherence to rigorous safety and quality standards. By addressing the challenges of patient compliance, cost-effectiveness, and accessibility, healthcare providers can integrate these interventions into hospital protocols effectively, paving the way for improved health outcomes and more efficient healthcare delivery (Tula *et al*., 2024).

Future Directions and Research

The field of microbiome research is rapidly advancing due to significant improvements in sequencing technologies and computational methods. High-throughput sequencing, such as next-generation sequencing (NGS), allows for comprehensive profiling of microbial communities in various human body sites. These advances enable researchers to identify the diversity and abundance of microorganisms more accurately, providing deeper insights into the complex interactions within the microbiome. Additionally, metagenomics, metatranscriptomics, and metabolomics are increasingly used to understand the functional capabilities and metabolic activities of microbiota, paving the way for more targeted and effective interventions. Personalized medicine is a growing trend in healthcare, and the microbiome is becoming a key focus for tailored therapeutic strategies. By analyzing an individual's microbiome composition and its interactions with the host, researchers can develop personalized probiotic and prebiotic interventions that cater to specific health needs (Kess-Momoh *et al*., 2024; Anaba *et al*., 2024). This approach holds the potential to improve efficacy and reduce adverse effects by considering the unique microbial and genetic makeup of each patient. Personalized microbiome-based interventions could revolutionize the treatment of various conditions, including gastrointestinal disorders, infections, and even metabolic and neurological diseases.

While short-term studies on probiotics and prebiotics have shown promising results, there is a lack of comprehensive data on their long-term effects. Understanding how these interventions impact the microbiome and overall health over extended periods is crucial for assessing their safety and efficacy. Longitudinal studies are needed to evaluate the sustainability of beneficial changes in the microbiome, the potential for resistance development, and any unintended consequences of prolonged use (Anaba *et al*., 2024). Such research will provide valuable insights into optimizing dosing regimens and identifying the most effective strategies for long-term health maintenance. The mechanisms by which the microbiome interacts with the immune system are complex and not yet fully understood. While it is known that certain microbial metabolites and components can modulate immune responses, the specific pathways and interactions remain to be elucidated. Further research is needed to dissect these mechanisms at the molecular and cellular levels. Understanding how different microbial species and their products influence immune function will aid in the development of targeted therapies that harness the microbiome’s immunomodulatory potential, ultimately leading to more precise and effective treatments (Juarez *et al*., 2022; Omotoye *et al*., 2024).

There is significant potential for the development of novel probiotic and prebiotic formulations that are more effective and versatile. Advances in genetic engineering and synthetic biology offer opportunities to design probiotics with enhanced functionalities, such as targeted pathogen inhibition, improved colonization capabilities, and production of beneficial compounds. Similarly, new prebiotics can be identified and synthesized to selectively promote the growth of health-promoting bacteria. Combining these innovations with existing knowledge will enable the creation of next-generation synbiotics that can address specific health issues more effectively (Obinna and Kess-Momoh, 2024). The integration of microbiome-based interventions with other medical treatments represents a promising area of research. For example, combining probiotics and prebiotics with antibiotics could mitigate the negative impact of antibiotics on the gut microbiota while enhancing their therapeutic effects. Additionally, integrating microbiome interventions with immunotherapies or cancer treatments could improve patient outcomes by modulating the immune system and reducing treatment-related side effects. This interdisciplinary approach requires collaborative research efforts to explore synergistic effects and develop comprehensive treatment protocols that leverage the microbiome's potential.

The future of microbiome research and its clinical applications is bright, with emerging trends focusing on advanced sequencing technologies and personalized interventions. Addressing current knowledge gaps, such as the long-term effects of interventions and the mechanisms underlying microbiome-immune interactions, is essential for optimizing therapeutic strategies. The development of novel formulations and the integration of microbiome-based therapies with other treatments hold promise for innovative healthcare solutions. Ongoing research and interdisciplinary collaboration will be key to unlocking the full potential of the human microbiome in improving health outcomes.

CONCLUSION

The human microbiome plays a crucial role in maintaining immune function and preventing hospital-acquired infections (HAIs). Its complex interactions with the immune system help to protect against pathogens, support immune homeostasis, and enhance overall health. Disruptions to the microbiome can compromise these protective mechanisms, leading to an increased risk of infections and other health complications. Probiotic and prebiotic interventions offer promising strategies for leveraging the microbiome to improve health outcomes. Probiotics provide beneficial bacteria that can restore and maintain a healthy microbiome, while prebiotics supply the necessary nutrients to support their growth and activity. Synbiotics, which combine both probiotics and prebiotics, enhance these benefits through synergistic effects, leading to better pathogen resistance, improved immune function, and enhanced mucosal barrier integrity.

The integration of microbiome-based interventions into clinical practice has the potential to significantly improve patient outcomes by reducing the incidence of HAIs. Effective use of probiotics, prebiotics, and synbiotics can help restore microbial balance, prevent infections, and support immune health. These benefits translate to shorter hospital stays, fewer complications, and reduced healthcare costs. Continued research into the microbiome and its interactions with the immune system will enhance our understanding of microbiome-based therapies. By elucidating the mechanisms underlying these interactions and identifying optimal strains and formulations, healthcare providers can develop more effective and targeted treatments. This knowledge will inform evidence-based practices and guide the implementation of microbiome interventions in clinical settings.

There is a need for ongoing research to address the current gaps in knowledge regarding the long-term effects of microbiome interventions and the specific mechanisms by which they modulate immune function. Researchers are encouraged to conduct longitudinal studies and explore new therapeutic avenues, such as genetically engineered probiotics and novel prebiotics. Collaborative efforts between scientists, clinicians, and industry partners will be essential to advance this field. Healthcare providers are urged to adopt evidence-based practices that incorporate microbiome-based interventions into standard care protocols. Training and educating healthcare professionals on the benefits, administration, and monitoring of probiotics and prebiotics are crucial for successful implementation. By embracing these innovative strategies, healthcare systems can improve patient care, reduce HAIs, and ultimately enhance public health outcomes.

Reference

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). AI-enhanced healthcare management during natural disasters: conceptual insights. *Engineering Science & Technology Journal*, *5*(5), 1794-1816.

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). A review of the challenges and opportunities in implementing health informatics in rural healthcare settings. *International Medical Science Research Journal*, *4*(5), 606-631.

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). Mental health management in healthcare organizations: Challenges and strategies-a review. *International Medical Science Research Journal*, *4*(5), 585-605.

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). Leveraging data analytics and IoT technologies for enhancing oral health programs in schools. *International Journal of Applied Research in Social Sciences*, *6*(5), 1005-1036.

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). Promoting health and educational equity: Cross-disciplinary strategies for enhancing public health and educational outcomes. *World Journal of Biology Pharmacy and Health Sciences*, *18*(2), 416-433.

Abdul, S., Adeghe, E.P., Adegoke, B.O., Adegoke, A.A., & Udedeh, E.H. (2024). Public-private partnerships in health sector innovation: Lessons from around the world. *Magna Scientia Advanced Biology and Pharmacy*, *12*(1), 045-059.

Adanma, U.M., & Ogunbiyi, E.O. (2024). A comparative review of global environmental policies for promoting sustainable development and economic growth. *International Journal of Applied Research in Social Sciences*, *6*(5), 954-977.

Adanma, U.M., & Ogunbiyi, E.O. (2024). Artificial intelligence in environmental conservation: evaluating cyber risks and opportunities for sustainable practices. *Computer Science & IT Research Journal*, *5*(5), 1178-1209.

Adanma, U.M., & Ogunbiyi, E.O. (2024). Assessing the economic and environmental impacts of renewable energy adoption across different global regions. *Engineering Science & Technology Journal*, *5*(5), 1767-1793.

Adanma, U.M., & Ogunbiyi, E.O. (2024). Evaluating the effectiveness of global governance mechanisms in promoting environmental sustainability and international relations. *Finance & Accounting Research Journal*, *6*(5), 763-791.

Adanma, U.M., & Ogunbiyi, E.O. (2024). The public health benefits of implementing environmental policies: A comprehensive review of recent studies. *International Journal of Applied Research in Social Sciences*, *6*(5), 978-1004.

Ahrodia, T., Das, S., Bakshi, S., & Das, B. (2022). Structure, functions, and diversity of the healthy human microbiome. *Progress in Molecular Biology and Translational Science*, *191*(1), 53-82.

Alam, M.T., Amos, G.C., Murphy, A.R., Murch, S., Wellington, E.M., & Arasaradnam, R.P. (2020). Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. *Gut Pathogens*, *12*, 1-8.

Amabebe, E., & Anumba, D.O. (2020). Female gut and genital tract microbiota-induced crosstalk and differential effects of short-chain fatty acids on immune sequelae. *Frontiers in Immunology*, *11*, 2184.

Anaba, D.C., Kess-Momoh, A.J., & Ayodeji, S.A. (2024). Digital transformation in oil and gas production: Enhancing efficiency and reducing costs. *International Journal of Management & Entrepreneurship Research*, *6*(7), 2153-2161.

Anaba, D.C., Kess-Momoh, A.J., & Ayodeji, S.A. (2024). Sustainable procurement in the oil and gas industry: Challenges, innovations, and future directions. *International Journal of Management & Entrepreneurship Research*, *6*(7), 2162-2172.

Averina, O.V., Poluektova, E.U., Marsova, M.V., & Danilenko, V.N. (2021). Biomarkers and utility of the antioxidant potential of probiotic Lactobacilli and Bifidobacteria as representatives of the human gut microbiota. *Biomedicines*, *9*(10), 1340.

Bashir, H., Bawa, A., & Kumar, R. (2022). Human microbiome: implication of age and external factors. In *Human Microbiome: Clinical Implications and Therapeutic Interventions* (pp. 1-26). Singapore: Springer Nature Singapore.

Blot, S., Ruppé, E., Harbarth, S., Asehnoune, K., Poulakou, G., Luyt, C.E., Rello, J., Klompas, M., Depuydt, P., Eckmann, C., & Martin-Loeches, I. (2022). Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. *Intensive and Critical Care Nursing*, *70*, 103227.

Cattaruzza, M.S., Gannon, J., Bach, K., Forberger, S., Kilibarda, B., Khader, Y., Okwor, U., & Bar-Zeev, Y. (2023). An e-book on industry tactics: preliminary results about readers' opinions and awareness. *Tobacco Prevention & Cessation*, *9*(Supplement).

Dahiya, D., & Nigam, P.S. (2023). Biotherapy using probiotics as therapeutic agents to restore the gut microbiota to relieve gastrointestinal tract inflammation, IBD, IBS and prevent induction of cancer. *International Journal of Molecular Sciences*, *24*(6), 5748.

Dekaboruah, E., Suryavanshi, M.V., Chettri, D., & Verma, A.K. (2020). Human microbiome: an academic update on human body site specific surveillance and its possible role. *Archives of Microbiology*, *202*, 2147-2167.

Dhingra, S., Rahman, N.A.A., Peile, E., Rahman, M., Sartelli, M., Hassali, M.A., Islam, T., Islam, S., & Haque, M. (2020). Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. *Frontiers in Public Health*, *8*, 535668.

Dimitri-Pinheiro, S., Soares, R., & Barata, P. (2020). The microbiome of the nose—friend or foe?. *Allergy & Rhinology*, *11*, 2152656720911605.

Friedrich, A.W. (2019). Control of hospital acquired infections and antimicrobial resistance in Europe: the way to go. *Wiener Medizinische Wochenschrift*, *169*(Suppl 1), 25-30.

Gannon, J., Bach, K., Cattaruzza, M.S., Bar-Zeev, Y., Forberger, S., Kilibarda, B., Azari, R., Okwor, U., Lomazzi, M., & Borisch, B. (2023). Big tobacco's dirty tricks: Seven key tactics of the tobacco industry. *Tobacco Prevention & Cessation*, *9*.

García-Montero, C., Fraile-Martínez, O., Gómez-Lahoz, A.M., Pekarek, L., Castellanos, A.J., Noguerales-Fraguas, F., Coca, S., Guijarro, L.G., García-Honduvilla, N., Asúnsolo, A., & Sanchez-Trujillo, L. (2021). Nutritional components in Western diet versus Mediterranean diet at the gut microbiota–immune system interplay. Implications for health and disease. *Nutrients*, *13*(2), 699.

Gou, H.Z., Zhang, Y.L., Ren, L.F., Li, Z.J., & Zhang, L. (2022). How do intestinal probiotics restore the intestinal barrier?. *Frontiers in Microbiology*, *13*,.929346.

Juarez, V.M., Montalbine, A.N., & Singh, A. (2022). Microbiome as an immune regulator in health, disease, and therapeutics. *Advanced Drug Delivery Reviews*, *188*, 114400.

Kess-Momoh, A.J., Tula, S.T., Bello, B.G., Omotoye, G.B., & Daraojimba, A.I. (2024). Strategic human resource management in the 21st century: A review of trends and innovations. *World Journal of Advanced Research and Reviews*, *21*(1), 746-757.

Kleintjes, W.G., Prag, R., Ebrahim, M., & Kotzee, E.P. (2020). The effect of probiotics for environmental cleaning on hospital-acquired infection in a burn centre: The results of a non-randomised controlled prospective study.

Krawczyk, B., Wityk, P., Gałęcka, M., & Michalik, M. (2021). The many faces of Enterococcus spp.—commensal, probiotic and opportunistic pathogen. *Microorganisms*, *9*(9), 1900.

Krocová, J., & Prokešová, R. (2022, January). Aspects of prevention of urinary tract infections associated with urinary bladder catheterisation and their implementation in nursing practice. In *Healthcare* (Vol. 10, No. 1, p. 152). MDPI.

Li, H.Y., Zhou, D.D., Gan, R.Y., Huang, S.Y., Zhao, C.N., Shang, A.O., Xu, X.Y., & Li, H.B. (2021). Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narrative review. *Nutrients*, *13*(9), 3211.

Melara, E.G., Avellaneda, M.C., Valdivié, M., García-Hernández, Y., Aroche, R., & Martínez, Y. (2022). Probiotics: Symbiotic relationship with the animal host. *Animals*, *12*(6), 719.

Mitrea, L., Nemeş, S.A., Szabo, K., Teleky, B.E., & Vodnar, D.C. (2022). Guts imbalance imbalances the brain: a review of gut microbiota association with neurological and psychiatric disorders. *Frontiers in medicine*, *9*, p.813204.

Newman, A.M., & Arshad, M. (2020). The role of probiotics, prebiotics and synbiotics in combating multidrug-resistant organisms. *Clinical Therapeutics*, *42*(9), 1637-1648.

Nwankwo, C.O., & Ihueze, C.C. (2018). Corrosion Rate Models for Oil and Gas Pipeline Systems A Numerical Approach. *International Journal of Engineering Research and Technology*.

Obinna, A.J., & Kess-Momoh, A.J. (2024). Comparative technical analysis of legal and ethical frameworks in AI-enhanced procurement processes. *World Journal of Advanced Research and Reviews*, *22*(1), 1415-1430.

Obiuto, N.C., Ebirim, W., Ninduwezuor-Ehiobu, N., Ani, E.C., Olu-lawal, K.A., & Ugwuanyi, E.D. (2024). Integrating sustainability into hvac project management: challenges and opportunities. *Engineering Science & Technology Journal*, *5*(3), 873-887.

Obiuto, N.C., Festus-Ikhuoria, I.C., Olajiga, O.K., & Adebayo, R.A. (2024). Reviewing the role of ai in drone technology and applications. *Computer Science & IT Research Journal*, *5*(4), 741-756.

Obiuto, N.C., Ninduwezuor-Ehiobu, N., Ani, E.C., & Andrew, K. (2024). Implementing circular economy principles to enhance safety and environmental sustainability in manufacturing.

Obiuto, N.C., Ninduwezuor-Ehiobu, N., Ani, E.C., Olu-lawal, K.A., & Ugwuanyi, E.D. (2024). Simulation-driven strategies for enhancing water treatment processes in chemical engineering: addressing environmental challenges. *Engineering Science & Technology Journal*, *5*(3), 854-872.

Obiuto, N.C., Olu-lawal, K.A., Ani, E.C., & Ninduwezuor-Ehiobu, N. (2024). Chemical management in electronics manufacturing: Protecting worker health and the environment. *World Journal of Advanced Research and Reviews*, *21*(3), 010-018.

Obiuto, N.C., Olu-lawal, K.A., Ani, E.C., Ugwuanyi, E.D., & Ninduwezuor-Ehiobu, N. (2024). Chemical engineering and the circular water economy: Simulations for sustainable water management in environmental systems. *World Journal of Advanced Research and Reviews*, *21*(3), 001-009.

Obiuto, N.C., Ugwuanyi, E.D., Ninduwezuor-Ehiobu, N., Ani, E.C., & Olu-lawal, K.A. (2024). Advancing wastewater treatment technologies: The role of chemical engineering simulations in environmental sustainability. *World Journal of Advanced Research and Reviews*, *21*(3), 019-031.

Ogunbiyi, E.O., Kupa, E., Adanma, U.M., & Solomon, N.O. (2024). Comprehensive review of metal complexes and nanocomposites: Synthesis, characterization, and multifaceted biological applications. *Engineering Science & Technology Journal*, *5*(6), 1935-1951.

Okpokoro, E., Lesosky, M., Osa-Afiana, C., Bada, F., Okwor, U., Odonye, G., Igbinomwanhia, V., Abdurrahman, S., Medugu, N., Kagina, B., & Abimiku, A.L. (2023). Prevalence and Risk factors for mycobacterium tuberculosis infection among health workers in HIV treatment centers in North Central, Nigeria. *The American Journal of Tropical Medicine and Hygiene*, *109*(1), 60-68.

Okpokoro, E., Okwor, U., Osa-Afiana, C., Odonye, G., Bada, F., & Igbinomwanhia, V., & Adams, S. 2022. Tuberculosis Infection Control Practice among Antiretroviral (ART) Clinics in North Central Nigeria. *Safety and Health at Work*, *13*, S108.

Okpokoro, E., Okwor, U., Osa-Afiana, C., Odonye, G., Bada, F., Igbinomwanhia, V., Adetiba, T., Abdurrahman, S., Nubwa, M., Lesosky, M., & Abimiku, A.L. (2022). Tuberculosis Infection Control Practice among Antiretroviral (ART) Clinics in North Central Nigeria. *Safety and Health at Work*, *13*, S108.

Olaboye, J.A. (2024). Implementing community-based medication reconciliation programs in the USA: Enhancing continuity of care and reducing errors. *International Medical Science Research Journal*, *4*(6), 694-702.

Olaboye, J.A. (2024). Optimizing healthcare resource allocation through data-driven demographic and psychographic analysis. *Computer Science & IT Research Journal*, *5*(6), 1488-1504.

Olaboye, J.A., Maha, C.C., Kolawole, T.O., & Abdul, S. (2024). Artificial intelligence in monitoring HIV treatment adherence: A conceptual exploration.

Olaboye, J.A., Maha, C.C., Kolawole, T.O., & Abdul, S. (2024). Big data for epidemic preparedness in southeast Asia: An integrative study.

Olaboye, J.A., Maha, C.C., Kolawole, T.O., & Abdul, S. (2024). Exploring deep learning: Preventing HIV through social media data.

Olaboye, J.A., Maha, C.C., Kolawole, T.O., & Abdul, S. (2024). Integrative analysis of AI-driven optimization in HIV treatment regimens. *Computer Science & IT Research Journal*, *5*(6), 1314-1334.

Olaboye, J.A., Maha, C.C., Kolawole, T.O., & Abdul, S. (2024). Innovations in real-time infectious disease surveillance using AI and mobile data. *International Medical Science Research Journal*, *4*(6), 647-667.

Oladimeji, R., & Owoade, Y. (2024). Navigating the digital frontier: empowering smbs with transformational strategies for operational efficiency, enhanced customer engagement, and competitive edge. *Journal of Scientific and Engineering Research*, *11*(5), 86-99.

Omotoye, G.B., Bello, B.G., Tula, S.T., Kess-Momoh, A.J., Daraojimba, A.I., & Adefemi, A. (2024). Navigating global energy markets: A review of economic and policy impacts. *International Journal of Science and Research Archive*, *11*(1), 195-203.

Roberts, M.B., & Fishman, J.A. (2021). Immunosuppressive agents and infectious risk in transplantation: managing the "net state of immunosuppression". *Clinical Infectious Diseases*, *73*(7), e1302-e1317.

Roope, L.S., Smith, R.D., Pouwels, K.B., Buchanan, J., Abel, L., Eibich, P., Butler, C.C., Tan, P.S., Walker, A.S., Robotham, J.V., & Wordsworth, S. (2019). The challenge of antimicrobial resistance: what economics can contribute. *Science*, *364*(6435), p.eaau4679.

Roselli, M., Canali, R., Finamore, A., Ghiselli, A., & Devirgiliis, C. (2022). Immune system, gut microbiota and diet: an interesting and emerging trialogue. In *Immunology of the GI Tract-Recent Advances*. IntechOpen.

Saleem, Z., Godman, B., Hassali, M.A., Hashmi, F.K., Azhar, F., & Rehman, I.U. (2019). Point prevalence surveys of health-care-associated infections: a systematic review. *Pathogens and global health*, *113*(4), 191-205.

Seidelman, J., & Anderson, D.J. (2021). Surgical site infections. *Infectious Disease Clinics*, *35*(4), 901-929.

Selby, L.M., Rupp, M.E., & Cawcutt, K.A. (2021). Prevention of central-line associated bloodstream infections: 2021 update. *Infectious Disease Clinics*, *35*(4), 841-856.

Sharif, S., Greer, A., Skorupski, C., Hao, Q., Johnstone, J., Dionne, J.C., Lau, V., Manzanares, W., Eltorki, M., Duan, E., & Lauzier, F. (2022). Probiotics in critical illness: A systematic review and meta-analysis of randomized controlled trials. *Critical Care Medicine*, *50*(8), 1175-1186.

Simpa, P., Solomon, N.O., Adenekan, O.A., & Obasi, S.C. (2024). Environmental stewardship in the oil and gas sector: Current practices and future directions. *International Journal of Applied Research in Social Sciences*, *6*(5), 903-926.

Simpa, P., Solomon, N.O., Adenekan, O.A., & Obasi, S.C. (2024). Nanotechnology's potential in advancing renewable energy solutions. *Engineering Science & Technology Journal*, *5*(5), 1695-1710.

Simpa, P., Solomon, N.O., Adenekan, O.A., & Obasi, S.C. (2024). Strategic implications of carbon pricing on global environmental sustainability and economic development: A conceptual framework. *International Journal of Advanced Economics*, *6*(5), 139-172.

Timsit, J.F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020). Bloodstream infections in critically ill patients: an expert statement. *Intensive care medicine*, *46*(2), 266-284.

Tula, S.T., Kess-Momoh, A.J., Omotoye, G.B., Bello, B.G., & Daraojimba, A.I. (2024). AI-enabled customer experience enhancement in business. *Computer Science & IT Research Journal*, *5*(2), 365-389.

Voidazan, S., Albu, S., Toth, R., Grigorescu, B., Rachita, A., & Moldovan, I. (2020). Healthcare associated infections—a new pathology in medical practice?. *International Journal of Environmental Research and Public Health*, *17*(3), 760.

Wiertsema, S.P., van Bergenhenegouwen, J., Garssen, J., & Knippels, L.M. (2021). The interplay between the gut microbiome and the immune system in the context of infectious diseases throughout life and the role of nutrition in optimizing treatment strategies. *Nutrients*, *13*(3), 886.

Wyeth, J. (2022). Infection prevention and control. In *Developing Practical Nursing Skills* (pp. 561-632). Routledge.

Yiek, W.K., Coenen, O., Nillesen, M., van Ingen, J., Bowles, E., & Tostmann, A. (2021). Outbreaks of healthcare-associated infections linked to water-containing hospital equipment: a literature review. *Antimicrobial Resistance & Infection Control*, *10*, 1-19.

Yoo, J.Y., Groer, M., Dutra, S.V.O., Sarkar, A., & McSkimming, D.I. (2020). Gut microbiota and immune system interactions. *Microorganisms*, *8*(10), 1587.

Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. *Cell Research*, *30*(6), 492-506.

Zommiti, M., Feuilloley, M.G., & Connil, N. (2020). Update of probiotics in human world: a nonstop source of benefactions till the end of time. *Microorganisms*, *8*(12), 1907.